# Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD

> **NCT06110130** · PHASE4 · RECRUITING · sponsor: **Washington D.C. Veterans Affairs Medical Center** · enrollment: 60 (estimated)

## Conditions studied

- Chronic Kidney Diseases

## Interventions

- **DRUG:** Empagliflozin 10 MG
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06110130
- **Lead sponsor:** Washington D.C. Veterans Affairs Medical Center
- **Sponsor class:** FED
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-02
- **Primary completion:** 2027-12-01
- **Final completion:** 2028-12-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-07-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06110130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06110130, "Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06110130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*